Parkinson's Foundation Identifies 2,000 Participants for Neuron23 Trial Through PD Trial Navigator

May 26, 2026
The Parkinson's Foundation has identified over 2,000 potential participants for Neuron23's NEULARK clinical trial using its new PD Trial Navigator program, which connects genetically eligible individuals with Parkinson's disease to relevant studies.

In a press release, the Parkinson's Foundation announced that its PD Trial Navigator pilot program has identified more than 2,000 potential participants for the NEULARK clinical trial, sponsored by Neuron23. The program aims to accelerate Parkinson's disease research by connecting eligible individuals to clinical trials based on their genetic profiles.

The PD Trial Navigator integrates data from the foundation's PD GENEration study, which since 2019 has provided genetic testing and counseling to over 30,000 people with Parkinson's. Participants who match specific genetic criteria can now be directly connected to clinical trial sites and receive guidance from trained Trial Navigators.

The NEULARK study focuses on individuals who have not yet started dopamine medication and show an overactive LRRK2 pathway, a factor present in about 30% of Parkinson's cases. Through PD Trial Navigator, these genetically suitable participants were identified across multiple regions, supporting Neuron23's precision medicine approach and helping streamline recruitment for the ongoing trial.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/26
Brain Navi Introduces NaoTrac Surgical Robot for Precision Neurosurgery
05/26
Neurophet and VHIR Begin Joint Study on AI Imaging for Multiple Sclerosis
05/26
Insilico Medicine and Human Longevity Partner on AI Foundation Model for Longevity Science
05/26
Deerborne Group to Attend ASCO 2026 and Highlight AI Platform COMPASS 360
05/26
Octagos Launches Ask Atlas for Cardiac Device Clinics

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

AI and the Law: Discussion Paper

This discussion paper explores the intersection of artificial intelligence and legal frameworks, addressing potential legal challenges posed by AI's autonomy, adaptiveness, and opacity. It examines issues such as liability gaps, causation, and the potential for granting AI systems legal personality, aiming to foster further discussion on AI's impact on law reform.

Read more

You May Also Like